Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-31
2006-10-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S339000
Reexamination Certificate
active
07129247
ABSTRACT:
The present invention relates to novel heterocyclyl-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
REFERENCES:
patent: 3948893 (1976-04-01), Aichinger et al.
patent: 4900751 (1990-02-01), Cox et al.
patent: 4973599 (1990-11-01), Gilman et al.
patent: 5028629 (1991-07-01), Hite et al.
patent: 5208253 (1993-05-01), Boschelli et al.
patent: 5776951 (1998-07-01), Arrowsmith et al.
patent: 5817862 (1998-10-01), Poetsch et al.
patent: 5883106 (1999-03-01), Stevens et al.
patent: 5883133 (1999-03-01), Schwark et al.
patent: 5912266 (1999-06-01), Perez
patent: 6110922 (2000-08-01), Link et al.
patent: 6211215 (2001-04-01), Momose et al.
patent: 392 788 (1991-06-01), None
patent: 2245586 (1997-08-01), None
patent: 2 123 383 (1971-02-01), None
patent: 0 219 756 (1987-04-01), None
patent: 0 262 845 (1988-04-01), None
patent: 0 455 356 (1991-11-01), None
patent: 0 710 654 (1996-05-01), None
patent: 0 835 867 (1998-04-01), None
patent: 0 887 340 (1998-12-01), None
patent: 1 052 238 (2000-11-01), None
patent: 2 117 760 (1983-10-01), None
patent: 2000-72766 (2000-03-01), None
patent: WO 96/26921 (1996-09-01), None
patent: WO 98/13347 (1998-04-01), None
patent: WO 98/39303 (1998-09-01), None
patent: WO 99/11258 (1999-03-01), None
patent: WO 99/20617 (1999-04-01), None
patent: WO 99/20618 (1999-04-01), None
patent: WO 99/49856 (1999-10-01), None
patent: WO 00/15604 (2000-03-01), None
patent: WO 00/15645 (2000-03-01), None
patent: WO 00/21920 (2000-04-01), None
patent: WO 00/39081 (2000-07-01), None
patent: WO 00/48989 (2000-08-01), None
patent: WO 00/59878 (2000-10-01), None
patent: WO 00/59880 (2000-10-01), None
patent: WO 00/60355 (2000-10-01), None
patent: WO 01/06984 (2001-02-01), None
patent: WO 01/07052 (2001-02-01), None
patent: WO 01/27102 (2001-04-01), None
Wang et al., “Amino-Substituted Heterocyles as Isosteres of Trans-Cinnamides: Design and Synthesis of Heterocyclic Biaryl Sulfides as Potent Antagonists of LFA-1/ICAM-1 Binding”,Bioorg. Med. Chem. Lett., 15:195-201 (2005) (available online as of Nov. 17, 2004 from http://www.sciencedirect.com).
U.S. Appl. No. 09/285,325, filed Apr. 2, 1999, Fowler et al.
U.S. Appl. No. 09/285,477, filed Apr. 2, 1999, Staunton et al.
U.S. Appl. No. 09/541,795, filed Mar. 31, 2000, Link et al.
U.S. Appl. No. 09/606,717, filed Jun. 29, 2000, Wang et al.
U.S. Appl. No. 09/695,040, filed Oct. 24, 2000, Gunawardana.
Ali et al., “Mechanisms of Inflammation and Leukocyte Activation”,Med. Clin. North America, 81:1-28 (1997).
Aoudjit et al., “Protection from Lymphoma Cell Metastasis in ICAM-1 Mutant Mice: A Posthoming Event”,J. Immunol., 161:2333-2338 (1998).
Bella et al., “The Structure of the Two Amino-Termiinal Domains of Human ICAM-1 Suggests How It Functions as a Rhinovirus Receptor and as an LFA-1 Integrin Ligand”,PNAS., 95:4140-4145 (1998).
Bennett et al., “An ICAM-1 Antisense Oligonucleotide Prevents and Reverses Dextran Sulfate Sodium-Induced Colitis in Mice”,J. Pharmacology Exper. Therapeutics, 280:988-1000 (1997).
Berge et al., “Pharmaceutical Salts”,J. Pharmaceutical Sciences, 66:1-19 (1977).
Binnerts et al., “How LFA-1 Binds to Different Ligands”,Immunol. Today, 20:240-245 (1999).
Bloemen et al., “LFA-1, and Not Mac-1, is Crucial for the Development of Hyperreactivity in a Murine Model of Nonallergic Asthma”,Am. J. Respir. Crit. Med., 153:521-529 (1996).
Boschelli et al., “Inhibition of E-Selectin-, ICAM-1-, and VCAM-0-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammatory Agent”,J. Med. Chem., 38:4597-4614 (1995).
Bowes et al., “Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Medical”,Experimental Neurology, 119:215-219 (1993).
Carlos et al., “Leukocyte-Endothelial Adhesion Molecules”,Blood, 84:2068-2101 (1994).
Chopp et al., “Postischemic Administration of an Anti-Mac-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats”,Stroke, 25:869-876 (1994).
Clark, et al., “Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule”,J. Neurosurg., 75;623-627 (1991).
Cosimi et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) In Nonhuman Primates with Renal Allografts”,J. Immunol., 144:4604-4612 (1990).
DeMeester et al., “Attenuation of Rat Lung Isograft Reperfusion Injury with a Combination of Anti-ICAM-1 and Anti-β2Integrin Monoclonal Antibodies”,Transplantation, 62:1477-1485 (1996).
Edwards et al., “Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-Associated Antigen-1”,J. Biol. Chem., 273:28937-28944 (1998).
Emeigh et al., “Small-Molecule Antagonists of LFA-1 Mediated Cell Adhesion”, 221stACS Nat'l Mtg, San Diego, CA, USA:MEDI 256 (2001).
Fisher et al., “Identification of the Binding Site Intercellular Adhesion Molecular 1 for Its Receptor, Leukocyte Function-Associated Antigen 1”,Mol. Biol. Cell, 8:501-515 (1997).
Gadek et al., “Identification and Characterization of Antagonists of the LFA-1/ICAM-1 Protein-Protein Interaction Novel Immunomodulatory Agents”,220th ACS Nat'l Mtg, Washington, DC, USA: MEDI 177 (2000).
Gahmberg, C., “Leukocyte Adhesion:CD11/CD18 Integrins and Intercellular Adhesion Molecules”,Curr. Opin. Cell. Biol., 9:643-650 (1997).
Gahmberg, C.G., “Leukocyte Adhesion: Structure and Function of Human Leukocyte β2-Integrins and Their Cellular Ligands”,Eur. J. Biochem., 245:215-232 (1997).
Green et al., “T Cell Receptor Stimulation, but Not CD28 Costimulation, Is Dependent on LFA-1-Mediated Events”,Eur. J. Immunol., 24:265-272 (1994).
Gorczynski et al., “A Role for Nonspecific (Cyclosporin A) or Specific (Monoclonal Antibodies to ICAM-1, LFA-1, and IL-10) Immunomodulation in the Prolongation of Skin Allografts After Antigen-Specific Pretransplant Immunization or Transfusion1”,J. Immunol., 152:2011-2019 (1994).
Gross et al., “Identification of LFA-1 as a Candidate Autoantigen in Treatment-Resistant Lyme Arthritis”,Science, 281:703-706 (1998).
Gute et al., “Inflammatory Responses toIschemiaand Reperfusion in Skeletal Muscle”,Mol. Cell. Biochem., 179:169-187 (1998).
Hallahan et al., “Intercellular Adhesion Molecule 1 Knockout Abrogates Radiation Induced Pulmonary Inflammation”,PNAS, 94:6432-6437 (1997).
Halloran et al., “Cellular Adhesion Molecules in Rat Adjuvant Arthritis”,Arthritis&Rheumatism, 39:810-819 (1996).
Hamilton et al., “Fluorenylalkanoic and Benzoic Acids as Novel Inhibitors of Cell Adhesion Processes in Leukocytes”,J. Med. Chem., 38:1650-1656 (1995).
Harning et al., “Reduction in the Severity of Graft-Versus-Host Disease and Increased Survival in Allogeneic Mice by Treatment with Monoclonal Antibodies to Cell Adhesion Antigens LFA-1α and MALA-2”,Transplantation, 52:842-845 (1991).
Hartman et al., “Protection of Ischemic/Reperfused Cainine Myocardium by CL18/6, a Monoclonal Antibody to Adhesion Molecule ICAM-1”,Cardiovascular Res., 30:47-54 (1995).
Hasegawa et al., “Prevention of Autoimmune Insulin-Dependent Diabetes in Non-Obese Diabetic Mice by Anti-LFA-1 and Anti-ICAM-1 mAb”,Int'l Immunology, 6:831-838 (1994).
He et al., “Effect of LFA-1 and ICAM-1 Antibody Treatment on Murine Corneal Allograft Survival”,Invest. Ophthalmol. Vis. Sci., 35:3218-3225 (1994).
Henricks et al., “Pharmacological Modulation of Cell Adhesion Molecules”,Eur. J
Gentles Robert
Wang Gary T.
Wang Sheldon
Abbott Laboratories
Coppins Janet L.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Saeed Kamal A.
LandOfFree
Aryl phenylheterocyclyl sulfide derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl phenylheterocyclyl sulfide derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl phenylheterocyclyl sulfide derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677684